Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Matrix metalloproteinase-13 (MMP13) is a highly regulated zinc-dependent endopeptidase and has been reported to be associated with vascular invasion and lymph node metastasis and predicts poor outcome for relatively early stage in esophageal squamous cell carcinoma (ESCC) patients. However, the role of the serum MMP-13 levels in ESCC is still unknown. In the present study, we investigate the clinical significance of MMP-13 levels in patients with ESCC. The serum level of MMP-13 was measured with commercially available ELISA kit in 112 healthy controls and 141 ESCC patients prior to surgical resection. Statistical associations between clinicopathological observations and MMP-13 levels were determined using the Mann-Whitney U test. The clinical value of MMP-13 level as a prognostic parameter was evaluated using the Cox's proportional hazards model. The results showed compared with the healthy control group (74.5±12.3 ng/ml), ESCC patients tended to have significantly higher serum MMP-13 concentrations (86.2 ± 14.6 ng/ml) (p < 0.05). Elevation of MMP-13 levels (≥ 76.4 ng/ml) was observed in 61.7% (87/141) of patients with ESCC, and 18.4% (26/141) in healthy controls. MMP-13 levels were associated with lymph node metastasis (p < 0.001), distant metastasis (p < 0.001), histological differentiation (p = 0.026), T classification (p < 0.005), but not with the tumor size, clinical stage, age and gender of the patients or tumor location. Multivariate analysis revealed that patients with an elevated level of MMP-13 (≥ 76.4 ng/ml) had significantly lower 5 year survival rate than those with non-elevated MMP-13 (< 76.4 ng/ml, log-rank p < 0.001). It is suggested that the elevated level of preoperative MMP-13 was found to associate with tumor progression and poor survival in patients with ESCC.